Core Viewpoint - Rockwell Automation Inc. (ROK) is expected to report strong earnings growth in its first-quarter fiscal 2026 results, with an estimated EPS of $2.54, reflecting a 38.8% year-over-year increase, and sales projected at $2.09 billion, indicating a 10.9% rise from the previous year [1][5]. Earnings Estimates - The Zacks Consensus Estimate for ROK's earnings has increased by 1.2% over the past 60 days [1][5]. - The earnings surprise history shows ROK has consistently beaten estimates, with an average surprise of 12.3% over the last four quarters [2][3]. Earnings Prediction Model - The model indicates a likely earnings beat for ROK, supported by a positive Earnings ESP of +1.03% and a Zacks Rank of 2 (Buy) [4][6]. Segment Performance Expectations - The Intelligent Devices segment is expected to see a 20.2% year-over-year sales increase to $968 million, with an operating profit of $175 million, up 45.6% [11]. - The Software & Control segment is projected to achieve sales of $568 million, reflecting a 7.5% growth, with an operating profit of $168 million, indicating a 26% increase [12]. - The Lifecycle Services segment is anticipated to report sales of $521 million, a 4.7% decline, with an operating profit of $51 million, suggesting a 25.4% decrease [13]. Market Context - ROK's stock has performed well, increasing by 60.9% over the past year, outperforming the industry average of 35.7% [14].

Core Viewpoint - Analysts expect Malibu Boats (MBUU) to report a quarterly loss of -$0.03 per share, reflecting a year-over-year decline of 109.7%, with revenues projected at $186.35 million, down 7% from the previous year [1] Group 1: Earnings Estimates - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [2] Group 2: Revenue Projections - Revenue by product for Malibu is estimated at $68.70 million, indicating a decline of 7.3% from the year-ago quarter [4] - Revenue by product for Cobalt is projected to reach $51.85 million, reflecting a decrease of 7.4% from the prior-year quarter [4] - Revenue by product for Saltwater Fishing is expected to be $66.05 million, showing a year-over-year change of -5.9% [5] Group 3: Unit Volume and Sales Metrics - Unit Volume by Segment for Malibu is projected at 490, down from 525 reported in the same quarter last year [5] - Unit Volume by Segment for Cobalt is expected to be 313, compared to 380 in the same quarter of the previous year [6] - The consensus for Net Sales per Unit - Total is $169,800, an increase from $163,895 reported in the same quarter last year [6] - Total Unit Volume is estimated at 1,098, down from 1,222 in the year-ago quarter [6] - Unit Volume by Segment for Saltwater Fishing stands at 295, compared to 317 in the same quarter of the previous year [7] Group 4: Stock Performance - Shares of Malibu Boats have increased by 11.1% over the past month, outperforming the Zacks S&P 500 composite, which moved up by 1.8% [7] - With a Zacks Rank of 3 (Hold), MBUU is expected to mirror overall market performance in the near future [7]

Core Insights - Wall Street analysts anticipate Bloom Energy (BE) will report quarterly earnings of $0.25 per share, reflecting a year-over-year decline of 41.9% [1] - Expected revenues for the quarter are projected at $649.12 million, which represents a 13.4% increase compared to the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1] Revenue Projections - Analysts estimate 'Revenue- Installation' to be $61.21 million, indicating a significant year-over-year increase of 69.6% [4] - The 'Revenue- Service' is expected to reach $76.43 million, reflecting a year-over-year growth of 42.1% [4] - 'Revenue- Electricity' is projected at $15.23 million, showing a year-over-year increase of 41% [4] - 'Revenue- Product' is anticipated to be $496.02 million, with a modest year-over-year growth of 5.2% [5] Profitability Metrics - The average prediction for 'Gross profit (loss)- Product' is estimated at $183.12 million, down from $218.08 million in the previous year [5] Stock Performance - Bloom Energy shares have increased by 50.3% over the past month, significantly outperforming the Zacks S&P 500 composite, which rose by 1.8% [5] - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [5]

Key Takeaways Equinor will report 4Q25 results on Feb. 4, with consensus EPS expected to fall 4.8% y/y to 60 cents.EQNR revenues are estimated at $23.44B, indicating a 15.2% decline, as Q4 crude prices fell sharply y/y.EQNR's plan to divest 40% of its Peregrino stake in the fourth quarter of 2025 may hit earnings.Equinor ASA (EQNR) is set to report fourth-quarter 2025 results on Feb. 4.In the last reported quarter, the large-cap integrated company’s adjusted earnings of 37 cents per share missed the Zacks C ...

Core Insights - Cigna Group (CI) is expected to report fourth-quarter 2025 results on February 5, 2026, with earnings estimated at $7.87 per share and revenues of $69.9 billion, reflecting an 18.5% year-over-year increase in earnings and a 6.5% increase in revenues [1][2] Financial Performance - For the full year 2025, Cigna's revenue is projected at $270 billion, indicating a 9.3% year-over-year growth, while the EPS consensus is $29.63, signaling an 8.4% growth year-over-year [2] - Cigna has beaten earnings estimates in three of the last four quarters, with an average surprise of negative 1.8% [2] Earnings Predictions - The current Earnings ESP for Cigna is 0.00% with a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat this quarter [3] - The consensus estimate for pharmacy revenues shows a 12.2% improvement year-over-year, while fees and other revenues are expected to grow by 12.1% [4] Segment Performance - Revenues from the Evernorth Health Services segment are projected at $59.2 billion, reflecting a 10.1% growth from the previous year, with pre-tax adjusted income expected to increase by 1.9% [5] - The medical care ratio (MCR) is estimated at 87.21%, down from 87.90% a year ago [5] Challenges - Cigna is facing a projected 22.2% decrease in premiums year-over-year and a decline in total medical customers from 19.1 million to 18.1 million [7] - A decline in net investment income is anticipated, with a consensus estimate suggesting a 5.1% year-over-year decrease [8]

Core Insights - Molina Healthcare, Inc. (MOH) is scheduled to report its fourth-quarter 2025 results on February 5, 2026, with earnings estimated at 43 cents per share and revenues at $10.8 billion [1][7]. Financial Performance - The fourth-quarter earnings estimate has remained stable over the past 60 days, indicating a year-over-year decrease of 91.5%, while revenues are projected to grow by 2.9% year over year [2]. - For the full year 2025, the revenue estimate stands at $44.89 billion, reflecting a 10.4% increase year over year, but the earnings per share estimate is $13.99, showing a decline of 38.23% year over year [3]. Membership and Premiums - Molina Healthcare expects to gain Medicare membership, while Medicaid membership is projected to decline by 6.4% year over year [7]. - The Zacks Consensus Estimate for premiums indicates a growth of 2.4% year over year in the fourth quarter, with Medicare premiums estimated at $1.4 billion, up 4.9% year over year [10]. Medical Care Ratio (MCR) and Costs - The consensus mark for the medical care ratio (MCR) in the marketplace is pegged at 94.8%, up from 83.3% a year ago, and the total MCR is expected to be around 93%, up from 90.2% [12]. - Rising costs and lower investment income contribute to uncertainty regarding earnings performance, with a projected 9.8% decline in investment income and a 6.1% increase in total operating expenses due to higher medical care costs and general administrative expenses [13]. Industry Context - Major peers such as UnitedHealth Group and Elevance Health have reported their fourth-quarter results, with UnitedHealth showing a 12% year-over-year revenue increase to $113.2 billion despite a 69% decline in adjusted earnings per share due to elevated medical costs [15]. - Elevance Health reported adjusted EPS of $3.33, surpassing estimates by 7.3%, driven by strong premium growth, although overall medical membership declined [16]. - The Cigna Group is projected to have an 18.5% year-over-year increase in earnings for the fourth quarter, with a 6.5% growth in revenues [17].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for CNA Financial despite an increase in revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - CNA Financial is expected to report quarterly earnings of $1.20 per share, reflecting a -4% change year-over-year, while revenues are projected to be $3.5 billion, up 5% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +11.67% for CNA Financial, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. Historical Performance - In the last reported quarter, CNA Financial exceeded the expected earnings of $1.25 per share by delivering $1.50, resulting in a surprise of +20.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Investment Considerations - While a positive earnings surprise can influence stock movement, other factors may also play a significant role in determining stock performance [15]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a likelihood of beating the consensus EPS estimate [12][10].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for iBio, Inc. despite lower revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - iBio is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +83.3% [3] - Revenues are projected to be $0.1 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 3.45% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +27.27% suggests analysts have become more optimistic about iBio's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - iBio currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, iBio was expected to post a loss of $0.07 per share but actually reported a loss of -$0.11, resulting in a surprise of -57.14% [13] - Over the past four quarters, iBio has only beaten consensus EPS estimates once [14] Industry Comparison - Bristol Myers Squibb is expected to report an EPS of $1.15 for the same quarter, indicating a year-over-year change of -31.1% [18] - Revenues for Bristol Myers are expected to be $12.25 billion, down 0.7% from the previous year [18] - The consensus EPS estimate for Bristol Myers has been revised down by 3.9% in the last 30 days, and it currently has an Earnings ESP of 0.00% [19][20]

Core Viewpoint - Canopy Growth Corporation (CGC) is expected to report its third-quarter fiscal 2026 results on February 6, with a projected revenue of $50.6 million and a loss per share of 3 cents, indicating a significant increase in losses compared to the previous year [1][2][9]. Financial Performance - In the last reported quarter, CGC posted a loss per share of 1 cent, which was 90.9% better than the Zacks Consensus Estimate [1]. - The Zacks Consensus Estimate for fiscal third-quarter revenues is $50.6 million, reflecting a decrease of 5.3% from the same quarter last year [2]. - The loss per share estimate for the fiscal third quarter has remained constant at 3 cents over the past 30 days [3]. Market Segments - Canopy's cannabis operations encompass both recreational and medical markets, with previous quarter results showing growth in cannabis revenues driven by adult-use and medical cannabis segments in Canada [4]. - Adult-use revenue growth in Canada may have been supported by strong consumer demand for infused pre-roll joints (PRJ) and the launch of All-In-One (AIO) vape products [5]. - Medical cannabis sales in Canada likely benefited from increased insured patient enrollments, larger average order sizes, and an expanded product portfolio under the Spectrum Therapeutics brand [5]. International Operations - International cannabis revenues are under pressure due to ongoing supply-chain and execution challenges in Europe, similar to trends from the previous quarter [6]. - The company has initiated a turnaround strategy focusing on operational oversight and transitioning back to internally produced Canadian GMP flower, which appears to be positively influencing performance [6]. Strategic Initiatives - During the quarter, CGC launched several strategic initiatives, including the Claybourne Gassers range of AIO vaporizers and expanded the Spectrum Therapeutics portfolio in Australia with new softgel capsule offerings [8]. - The company also entered into an agreement to acquire all issued and outstanding common shares of MTL Cannabis Corp., indicating a focus on portfolio optimization and market consolidation [10].

Core Viewpoint - Fortinet (FTNT) is expected to report quarterly earnings of $0.74 per share, with revenues projected at $1.86 billion, reflecting an 11.9% increase year-over-year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.8% over the past 30 days, indicating analysts have reassessed their projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenue- Services' at $1.22 billion, a 12.1% increase from the prior year [5]. - 'Revenue- Product' is projected to reach $638.84 million, reflecting an 11.3% year-over-year change [5]. - The consensus for 'Revenue- Services- Security subscription' stands at $689.70 million, indicating a 10.3% increase from the previous year [5]. - 'Revenue- Services- Technical support and other' is expected to be $525.70 million, a 14.1% increase year-over-year [6]. - 'Revenue- Europe Middle East and Africa' is projected at $761.61 million, showing a 10% year-over-year change [6]. - 'Geographic revenues- Americas' are expected to reach $740.08 million, reflecting an 11.1% increase [7]. - 'Revenue- Asia Pacific and Japan' is estimated at $353.88 million, indicating a 17.2% increase from the prior year [7]. Financial Metrics - Total billings (Non-GAAP) are forecasted to reach $2.24 billion, up from $2.00 billion year-over-year [7]. - Total deferred revenue is expected to be $7.03 billion, compared to $6.36 billion in the same quarter last year [8]. - 'Gross profit- Product Non-GAAP' is projected at $413.23 million, up from $397.50 million year-over-year [8]. - 'Gross profit- Service Non-GAAP' is estimated at $1.06 billion, compared to $962.50 million in the previous year [9]. - 'Gross profit- Product' is expected to reach $403.14 million, up from $396.00 million year-over-year [9]. Stock Performance - Fortinet shares have increased by 4.3% over the past month, outperforming the Zacks S&P 500 composite, which rose by 0.7% [9].